PD-1阻害薬及びPD-L1阻害薬の世界市場動向:競争状況、パイプライン及び市場分析

◆英語タイトル:PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015
◆商品コード:DELV504252
◆発行会社(調査会社):DelveInsight
◆発行日:2015年4月1日
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,950 ⇒換算¥336,300見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,800 ⇒換算¥661,200見積依頼/購入/質問フォーム
Enterprise License(複数国内共有可)USD8,850 ⇒換算¥1,008,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

Summary:
DelveInsight Report, “PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015” analyses that PD-1 and PD-L1 inhibitors are among the highly targeted mechanisms in oncology. There are 34 drugs are in pipeline. Out of 34 drugs, 22 are in combinations with other therapeutics agents. Focus of development is mainly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) and Programmed death-ligand 1 (PD-L1). Continuation of expansion of the combination regimens is likely to be one of the main themes surrounding immunotherapies as these partnerships are the key to developing competitively strong therapy regimens.
According to DelveInsight, the future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. The market for PD-1 and PD-L1 drugs might be billions of dollars richer than many believe. These drugs which include Bristol-Myers’ Opdivo and Merck’s Keytruda, are going to be Blockbuster in upcoming years.

Scope
• Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors
• DelveInsight report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets
• It also includes Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies

• Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market

• Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates

• Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.

Reasons to Buy

• DelveInsight report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for PD-1 and PD-L1 inhibitors.
• Develop business strategies by understanding the trends shaping and driving for Immunotherapeutics market
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding PD-a and PD-L1 inhibitors pipeline in-depth
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners to enhance and expand business potential and scope
• Identifying the upcoming leaders in the PD-1 and PD-L1 inhibitors market in the coming years.

【レポートの目次】

Introduction 2

Executive Summary 3

Programmed Death 1 (PD-1) 9
Programmed Death Ligand 1 (PD-L1) 10
Role of PD-1 and PD-L1 pathways 11
MOA of PD-1 and PD-L1 inhibitors 12
Significance of PD-1 and PD-L1 inhibitors 13
PD-1 and PDL-1 Active Therapy Areas & Epidemiology 14
Metastatic Renal Cell Carcinoma 14
Epidemiology 14
Squamous Cell Carcinomas of the Head and Neck 15
Epidemiology 15
Metastatic Colorectal Cancer 16
Epidemiology 16
Gastric Cancer 17
Epidemiology 17
Biomarkers – PD-1 and PD-L1 inhibitors 18

Market Overview 20
Comparative Analysis of Pipeline & Marketed Drugs 20
Marketed Product of PD-1 and PD-L1 drugs -Overview 21
Marketed Drug Candidate Profiles 22
Pembrolizumab 22
Nivolumab 23
Marketed Drugs Sales 24
Details of patent expiry of marketed drugs 25
Current and Future Market for PD and PD-L1 inhibitors: 26
Challenges and Barriers associated with use of PD and PD-L1 inhibitors: 28
Anti–PD-1 Agents in Non–Small Cell Lung Cancer 29
Anti–PD-1 Agents in Triple-Negative Breast Cancer 29
Anti–PD-1 Agents in Melanoma 29
Combination therapy 30

Pipeline Therapeutics 31
An overview of pipeline products 31
Therapeutics under Development by MOA 33
Therapeutics under Development by Indication 34
Therapeutics under Development by Companies 37

Drug Candidate Profiles 39

Therapeutic Assessment of pipeline 72
Therapeutics under Development by Product Type 72
Therapeutics under Development by Phases for Monotherapy 73
Therapeutics under Development by Phases for Combination Products 74
Therapeutics under Development by Route of Administration of Monotherapy 75
Therapeutics under Development by Route of Administration of Combination Products 76
Industry Financial- Company Profiles 77

SWOT Analysis 82
Market Research Methodology 83
Research Design 83
Contact Us 85
Disclaimer 85

[List of Tables] Table 1: Number of Products Under Development and Marketed forPD-1 and PD-L1 Drugs , 2015 20
Table 2: PD-1 Marketed Drugs, 2015 21
Table 3: Sales of Marketed drugs, 2015 24
Table 4: Details of patent expiry of marketed molecules, 2015 25
Table 5: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2015 32
Table 6: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs by MOA, 2015 33
Table 7: Number of Products Under Development for PD-1 and PD-L1 Drugs by Indication, 2015 34
Table 8: Number of Products under Development by Companies, 2015 37
Table 9: Number of Products Under Development forPD-1 and PD-L1 Drugs, 2015 72
Table 10: Number of Products Under Development forPD-1 and PD-L1 inhibitor Drugs (Molecule Type Single), 2015 73
Table 11: Number of Products Under Development forPD-1 and PD-L1 Drugs (Combination Type Product), 2015 74
Table 12: Number of Products under Development by Route of Administration Single Type Product, 2015 75
Table 13: Number of Products under Development by Route of Administration Combination Type Product, 2015 76

[List of figures] Figure 1: T cell interaction with cancer 9
Figure 2: PD-L1/PD-1 Pathway 11
Figure 3: MOA of PD-1 and PD-L1 12
Figure 4: Number of Products under Development and Marketed for PD-1 and PD-L1 Drugs, 2015 20
Figure 5: Sales of marketed drugs, 2015 24
Figure 6: Details of patent expiry of marketed molecules, 2015 25
Figure 7: Number of Products under Development for PD-1 and PD-L1 inhibitors Drugs, 2015 31
Figure 8 Products under Development by MOA, 2015 33
Figure 9 Products under Development by Indication, 2015 34
Figure 10: Number of Products by Product Type for PD-1 and PD-L1Inhibitor Drugs, 2015 72
Figure 11: Number of Products under Development for PD-1 and PD-L1 inhibitor Drugs (Molecule Type Single), 2015 73
Figure 12: Number of Products under Development for PD-1 and PD-L1 Drugs (Combination Type Product), 2015 74
Figure 13: Percentage of pipeline drugs by Route of Administration of Single Type Product (%), 2015 75
Figure 14: Percentage of pipeline drugs by Route of Administration of Combination Type Product (%), 2015 76



【レポートのキーワード】

PD-1(Programmed Death 1)阻害薬、PD-L1(Programmed Death Ligand 1)阻害薬、治療、製薬、パイプライン、治験、がん治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[PD-1阻害薬及びPD-L1阻害薬の世界市場動向:競争状況、パイプライン及び市場分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆